AU4402500A - Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna - Google Patents

Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna

Info

Publication number
AU4402500A
AU4402500A AU44025/00A AU4402500A AU4402500A AU 4402500 A AU4402500 A AU 4402500A AU 44025/00 A AU44025/00 A AU 44025/00A AU 4402500 A AU4402500 A AU 4402500A AU 4402500 A AU4402500 A AU 4402500A
Authority
AU
Australia
Prior art keywords
human bcl
mrna
directed against
oligonucleotide derivatives
derivatives directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44025/00A
Inventor
Dieter Huesken
Gerd Ludke
Uwe Zangemeister-Wittke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Zuerich
Original Assignee
Universitaet Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Zuerich filed Critical Universitaet Zuerich
Publication of AU4402500A publication Critical patent/AU4402500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU44025/00A 1999-04-30 2000-04-26 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna Abandoned AU4402500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9910119.8A GB9910119D0 (en) 1999-04-30 1999-04-30 Organic compounds
GB9910119 1999-04-30
PCT/EP2000/003708 WO2000066724A2 (en) 1999-04-30 2000-04-26 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna

Publications (1)

Publication Number Publication Date
AU4402500A true AU4402500A (en) 2000-11-17

Family

ID=10852654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44025/00A Abandoned AU4402500A (en) 1999-04-30 2000-04-26 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna

Country Status (4)

Country Link
EP (1) EP1181361A2 (en)
AU (1) AU4402500A (en)
GB (1) GB9910119D0 (en)
WO (1) WO2000066724A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2832154B1 (en) * 2001-11-09 2007-03-16 Centre Nat Rech Scient OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE
DE10258677A1 (en) * 2002-12-13 2004-06-24 Elez, Vera, Dr. Combined use of antisense oligonucleotides for treating cancer, directed against the Polo-like kinase 1 and B cell leukemia/lymphoma 2 genes, having a synergistic effect
FR2852606A1 (en) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med In vitro method for simultaneous inhibition of several genes, useful for treating cancer or viral infection, using a ligand that binds to a common site in the genes and induces cutting by topoisomerase
CA3100140C (en) 2014-01-28 2023-10-24 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470974A (en) * 1985-03-15 1995-11-28 Neu-Gene Development Group Uncharged polynucleotide-binding polymers
EP0722342B1 (en) * 1993-09-20 2004-12-29 The Trustees Of The University Of Pennsylvania REGULATION OF bcl-2 GENE EXPRESSION
WO1995031470A2 (en) * 1994-05-13 1995-11-23 Merck Frosst Canada Inc. Antisense inhibitors of gene expression
US5874566A (en) * 1996-10-25 1999-02-23 Hisamitsu Pharmaceutical Co. Inc. Il-15 triplex oligonucleotides
EP1093373A4 (en) * 1998-07-02 2005-04-13 Univ Columbia OLIGONUCLEOTIDE INHIBITORS OF bcl-xL
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Also Published As

Publication number Publication date
WO2000066724A3 (en) 2001-02-08
GB9910119D0 (en) 1999-06-30
WO2000066724A2 (en) 2000-11-09
EP1181361A2 (en) 2002-02-27

Similar Documents

Publication Publication Date Title
HK1048999A1 (en) Azepinoindole derivatives, their preparation and use thereof
AU3620600A (en) Skin-marking devices and their use
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
AU2208401A (en) Inhibitors of complement activation, their preparation and use
AU715620C (en) Therapeutic methods and uses
AU5161399A (en) N-benzocycloalkyl-amide derivatives and their use as medicaments
AU1164601A (en) Therapeutic use and formulation
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
AU6635800A (en) Pyridomorphinans, thienomoprhinans and use thereof
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
EP1194147A4 (en) Arylthiazolidinedione and aryloxazolidinedione derivatives
HK1041200A1 (en) Cyclopentanone derivatives and their use
AU3971500A (en) Indazole derivatives, preparation and therapeutic application thereof
AU7601400A (en) Treatment and prevention of hepatic disorders
AU3732500A (en) Beclin and uses thereof
AU4402500A (en) Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna
AU1053501A (en) Polyazanaphthalene compound and medicinal use thereof
AU2669201A (en) Taccalonolides and their use
IL135452A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
AU1685201A (en) Drug inducible system and use thereof
AU1564300A (en) NF-kB activation inhibitors, and their pharmaceutical uses
AU5974100A (en) 6-carboxyphenyldihydropyridazinone derivatives and use thereof
AU5979300A (en) Angiopoietin-6 and uses thereof
AU5524400A (en) Novel 6-amino-uracil derivatives, preparation and use thereof
AU6150400A (en) Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase